Frontiers in Endocrinology (May 2021)
Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
- Yuheng Hu,
- Yuheng Hu,
- Yuheng Hu,
- Yuheng Hu,
- Zeng Ye,
- Zeng Ye,
- Zeng Ye,
- Zeng Ye,
- Fei Wang,
- Fei Wang,
- Fei Wang,
- Fei Wang,
- Yi Qin,
- Yi Qin,
- Yi Qin,
- Yi Qin,
- Xiaowu Xu,
- Xiaowu Xu,
- Xiaowu Xu,
- Xiaowu Xu,
- Xianjun Yu,
- Xianjun Yu,
- Xianjun Yu,
- Xianjun Yu,
- Shunrong Ji,
- Shunrong Ji,
- Shunrong Ji,
- Shunrong Ji
Affiliations
- Yuheng Hu
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Yuheng Hu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Yuheng Hu
- Shanghai Pancreatic Cancer Institute, Shanghai, China
- Yuheng Hu
- Pancreatic Cancer Institute, Fudan University, Shanghai, China
- Zeng Ye
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Zeng Ye
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Zeng Ye
- Shanghai Pancreatic Cancer Institute, Shanghai, China
- Zeng Ye
- Pancreatic Cancer Institute, Fudan University, Shanghai, China
- Fei Wang
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Fei Wang
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Fei Wang
- Shanghai Pancreatic Cancer Institute, Shanghai, China
- Fei Wang
- Pancreatic Cancer Institute, Fudan University, Shanghai, China
- Yi Qin
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Yi Qin
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Yi Qin
- Shanghai Pancreatic Cancer Institute, Shanghai, China
- Yi Qin
- Pancreatic Cancer Institute, Fudan University, Shanghai, China
- Xiaowu Xu
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Xiaowu Xu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Xiaowu Xu
- Shanghai Pancreatic Cancer Institute, Shanghai, China
- Xiaowu Xu
- Pancreatic Cancer Institute, Fudan University, Shanghai, China
- Xianjun Yu
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Xianjun Yu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Xianjun Yu
- Shanghai Pancreatic Cancer Institute, Shanghai, China
- Xianjun Yu
- Pancreatic Cancer Institute, Fudan University, Shanghai, China
- Shunrong Ji
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Shunrong Ji
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Shunrong Ji
- Shanghai Pancreatic Cancer Institute, Shanghai, China
- Shunrong Ji
- Pancreatic Cancer Institute, Fudan University, Shanghai, China
- DOI
- https://doi.org/10.3389/fendo.2021.679000
- Journal volume & issue
-
Vol. 12
Abstract
Pancreatic neuroendocrine tumors (pNETs) are rare and part of the diverse family of neuroendocrine neoplasms (NENs). Somatostatin receptors (SSTRs), which are widely expressed in NENs, are G-protein coupled receptors that can be activated by somatostatins or its synthetic analogs. Therefore, SSTRs have been widely researched as a diagnostic marker and therapeutic target in pNETs. A large number of studies have demonstrated the clinical significance of SSTRs in pNETs. In this review, relevant literature has been appraised to summarize the most recent empirical evidence addressing the clinical significance of SSTRs in pNETs. Overall, these studies have shown that SSTRs have great value in the diagnosis, treatment, and prognostic prediction of pNETs; however, further research is still necessary.
Keywords
- somatostatin receptor
- pancreatic neuroendocrine tumor
- somatostatin analog
- peptide receptor radionuclide therapy
- somatostatin receptor imaging
